Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00821093 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,123
- Enrollment target
NCT00821093 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,123 participants.
The verdict
NCT00821093, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,123 participants
- Enrollment target
Study Summary
This study compared the safety and efficacy of indacaterol 150 µg taken once daily (o.d.) versus salmeterol 50 µg taken twice daily (b.i.d) in patients 40 years old or older with chronic obstructive pulmonary disease.
Interventions
- DRUG Placebo to indacaterol
- DRUG Placebo to salmeterol
- DRUG Indacaterol 150 µg
- DRUG Salmeterol 50 µg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,123 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00821093
The ClinicalTrials.gov registry entry for NCT00821093 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo to indacaterol is the first listed.
NCT00821093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00821093 about?
NCT00821093 is a clinical study titled "Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)". This study compared the safety and efficacy of indacaterol 150 µg taken once daily (o.d.) versus salmeterol 50 µg taken twice daily (b.i.d) in patients 40 years old or older with chronic obstructive pulmonary disease.
What is the current status of trial NCT00821093?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,123 participants. The study started on 2009-01. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00821093?
The interventions under investigation include: Placebo to indacaterol (DRUG), Placebo to salmeterol (DRUG), Indacaterol 150 µg (DRUG), Salmeterol 50 µg (DRUG).
Who is sponsoring clinical trial NCT00821093?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.